INS and diabetes mellitus: The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial focused on adults aged ≥ 50 years with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk factors, and this trial investigated subjects with HbA1c ≤ 9.5%, receiving up to two oral glucose-lowering drugs with or without basal insulin, and a body mass index of at least 23 kg/m2.